Valeo Financial Advisors’s BioCryst Pharmaceuticals BCRX Stock Holding History

Valeo Financial Advisors’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-27,000	Closed	-$286K	–	512
2022 Q2	$286K	Sell	27,000 -500	-2%	-$5.16K	0.02%	359
2022 Q1	$447K	Sell	27,500 -324	-1%	-$5.2K	0.02%	350
2021 Q4	$385K	Sell	27,824 -500	-2%	-$6.62K	0.02%	363
2021 Q3	$407K	Hold	28,324	–	–	0.02%	347
2021 Q2	$448K	Sell	28,324 -500	-2%	-$6.79K	0.03%	281
2021 Q1	$293K	Sell	28,824 -8,376	-23%	-$86.4K	0.01%	361
2020 Q4	$277K	Buy	37,200 +17,500	+89%	+$90.2K	0.01%	353
2020 Q3	$68K	Buy	19,700 +15,500	+369%	+$66.4K	0.01%	567
2020 Q2	$20K	Buy	+4,200	New	+$16.8K	﹤0.01%	1053

Other funds holding BCRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

RP Management New York $139M AUM 37.98% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Valeo Financial Advisors's BCRX Position: Q3 2022 in Review

Valeo Financial Advisors sold out of BioCryst Pharmaceuticals (BCRX) in Q3 2022, closing a stake of 27,000 shares — an estimated $286K sold.

Valeo Financial Advisors first reported a position in BCRX in Q2 2020 and held it in 9 quarters. The position peaked at $448K in Q2 2021. 234 funds tracked by Wall St. Rank hold BCRX as of Q3 2022.

Valeo Financial Advisors reported no remaining BioCryst Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
Valeo Financial Advisors sold 27,000 BioCryst Pharmaceuticals shares in Q3 2022, an estimated $286K.
Valeo Financial Advisors first reported a position in BioCryst Pharmaceuticals in Q2 2020 and held it in 9 quarters.
Valeo Financial Advisors's BioCryst Pharmaceuticals position peaked at $448K in Q2 2021.
234 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2022.

Based on Valeo Financial Advisors's 13F filing for Q3 2022, filed 31 Oct 2022.